8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India. (linkinghub.elsevier.com)

Authors: Goel A … Aggarwal R Journal: The Lancet Published: 2026-09-30 DOI: https://doi.org/10.1016/S0140-6736(26)01380-2